Anti-Cancer Medicines Availability Study

AntiNeoplastics Medicines Availability study banner

Study objectives: to provide health authorities with data on the availability of licensed anti-neoplastic medicines in Europe and worldwide

The results of the European study have been published in the August 2016 issue of Annals of Oncology. The accompanying ESMO press release can be viewed here

Read more about the European study  Read more about the International study

Cancer patients are ending up in debt because they have to cover the costs of treatment as well as other care related expenses. The accompanying ESMO Asia 2016 press release can be viewed here.

Study objectives

  • to provide health authorities with data on the availability of licensed anti-neoplastic medicines
  • to report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
  • to provide data so that policy makers can decide how to best address and resolve the challenges identified

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings